Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

https://doi.org/10.1182/blood-2022-157873

Published: 2022

Journal Articles

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Alexander Coltoff, Andrew H. Lipsky, Todd L. Rosenblat, Jennifer E. Amengual, Mark L Heaney, Joseph G. Jurcic, Nicole Lamanna

Blood (2022) 140 (Supplement 1): 9893–9895.

https://doi.org/10.1182/blood-2022-167191

Published: 2022

Journal Articles

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 1518–1521.

https://doi.org/10.1182/blood-2022-156936

Published: 2022

Journal Articles

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, Vinod A. Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L Heaney, Jessica Sachs, Lei Sun, Amanda Pilla, Benjamin Exter, Hina A. Jolin, Tsewang Tashi

Blood (2022) 140 (Supplement 1): 1512–1513.

https://doi.org/10.1182/blood-2022-156311

Published: 2022

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Andrew H. Lipsky, Brian T. Hill, Allison M. Winter, Joseph G. Jurcic, Mark L. Heaney, Todd L. Rosenblat, Matthew Chiaramonte, Hanna Weissbrot, Nicole Lamanna

Blood (2021) 138 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2021-150914

Published: 2021

Journal Articles

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew T. Kuykendall, Casey L. O'Connell, Jamile M. Shammo, Angela Fleischman, Ruben A. Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta, John Mascarenhas

Blood (2021) 138 (Supplement 1): 240.

https://doi.org/10.1182/blood-2021-148020

Published: 2021

Journal Articles

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136632

Published: 2020

Journal Articles

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Alexander Coltoff, MD, Joseph G. Jurcic, MD, Peter Campbell, PharmD, BCOP, Daniel J. Lee, MD, Mark L Heaney, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD MS, Mark G. Frattini, MDPhD, George Vlad, PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-134237

Published: 2020

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Blood (2020) 135 (19): 1696–1703.

https://doi.org/10.1182/blood.2019003347

Published: 2020

Includes: Supplemental data

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database

Blood (2019) 134 (Supplement_1): 2949.

https://doi.org/10.1182/blood-2019-121533

Published: 2019

Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD

Blood (2019) 134 (Supplement_1): 3899.

https://doi.org/10.1182/blood-2019-130203

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Blood (2018) 132 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2018-99-111935

Published: 2018

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Blood (2014) 124 (21): 1954.

https://doi.org/10.1182/blood.V124.21.1954.1954

Published: 2014

Journal Articles

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Eli L. Diamond, Lorenzo Dagna, David M. Hyman, Giulio Cavalli, Filip Janku, Juvianee Estrada-Veras, Marina Ferrarini, Omar Abdel-Wahab, Mark L. Heaney, Paul J. Scheel, Nancy K. Feeley, Elisabetta Ferrero, Kenneth L. McClain, Augusto Vaglio, Thomas Colby, Laurent Arnaud, Julien Haroche

Blood (2014) 124 (4): 483–492.

https://doi.org/10.1182/blood-2014-03-561381

Published: 2014

Includes: Supplemental data

Journal Articles

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Robert J. Arceci, M.D., Ph.D., Carl E. Allen, MD, PhD, Ira Dunkel, M.D., Eric D. Jacobsen, MD, James Whitlock, Robert Vassallo, M.D., Ivan M. Borrello, MD, Allen Oliff, MD, Shannon R. Morris, MD, PhD, Beth Ann M Reedy, Alison Portnoy, Deborah A. Smith, PharmD, Bob Noble, Amy A. Murnane, Stephen A. Szabo, Carlos Rodriguez-Galindo, Mark L. Heaney, MD, PhD, Kenneth L. McClain, MD, PhD, Sarah Vaseilbuh, MD

Blood (2013) 122 (21): 2907.

https://doi.org/10.1182/blood.V122.21.2907.2907

Published: 2013

NARROW

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only